Blood Glucose-lowering Activity of Colestimide in Patients with Type 2 Diabetes and Hypercholesterolemia: A Case-control Study Comparing Colestimide with Acarbose

Suzuki, Tatsuya; Oba, Koji; Futami, Shoko; Suzuki, Kazunari; Ouchi, Motoshi; Igari, Yoshimasa; Matsumura, Noriaki; Watanabe, Kentaro; Kigawa, Yoshiaki; Nakano, Hiroshi

doi:10.1272/jnms.73.277

Cited by 38 publications

(27 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas the size of the total bile acid pool was not different, T2DM subjects demonstrated increased deoxycholic acid input rates and cholic acid synthesis rates but exhibited a lower proportion of CDCA. Furthermore, therapy with bile acid sequestrants leads to the expected reductions in both total cholesterol and low-density lipoprotein cholesterol as well as improvements in glycaemic control in T2DM patients (Garg & Grundy 1994, Suzuki et al 2006, Zieve et al 2007, Kondo & Kadowaki 2010. Compared with patients who received control treatments or placebos, T2DM patients given bile acid sequestrants demonstrated greater reductions in the levels of plasma glucose and HbA1c.…”

Section: Mmol/l) (World Health Organization 2006)mentioning

confidence: 99%

Metabolomics in diabetes research

Friedrich¹

2012

Journal of Endocrinology

124

View full text Add to dashboard Cite

Diabetes represents one of the most important global health problems because it is associated with a large economic burden on the health systems of many countries. Whereas the diagnosis and treatment of manifest diabetes have been well investigated, the identification of novel pathways or early biomarkers indicative of metabolic alterations or insulin resistance related to the development of diabetes is still in progress. Over half of the type 2 diabetes patients show manifestations of diabetes-related diseases, which highlight the need for early screening markers of diabetes. During the last decade, the rapidly growing research field of metabolomics has introduced new insights into the pathology of diabetes as well as methods to predict disease onset and has revealed new biomarkers. Recent epidemiological studies first used metabolism to predict incident diabetes and revealed branched-chain and aromatic amino acids including isoleucine, leucine, valine, tyrosine and phenylalanine as highly significant predictors of future diabetes. This review summarises the current findings of metabolic research regarding diabetes in animal models and human investigations.

show abstract

Section: Mmol/l) (World Health Organization 2006)mentioning

confidence: 99%

Metabolomics in diabetes research

Friedrich¹

2012

Journal of Endocrinology

124

View full text Add to dashboard Cite

show abstract

“…A case control study included 33 patients with type 2 diabetes and hypercholesterolemia whose postprandial glucose levels were not well controlled with oral antidiabetic agents. 65 Treatment with colestimide 3 g/d reduced fasting plasma glucose (from 124.9 6 21.1 mg/dL to 116.2 6 19.9 mg/dL), postprandial glucose (from 216.9 6 37.2 mg/dL to 191.1 6 40.9 mg/dL; P = 0.008), total cholesterol (from 223 6 32 mg/dL to 184 6 29 mg/dL; P , 0.001), and triglyceride levels (from 203 6 123 mg/dL to 175 6 92 mg/dL). 65 A similar study was carried out to investigate the glycemic and lipid effects of colestimide in 70 patients with type 2 diabetes receiving treatment with oral antidiabetic agents or insulin who had baseline LDL-C .3.6 mmol/L.…”

Section: Clinical Evidence Of Bile Acid Sequestrants Improving Glycemmentioning

confidence: 99%

“…65 Treatment with colestimide 3 g/d reduced fasting plasma glucose (from 124.9 6 21.1 mg/dL to 116.2 6 19.9 mg/dL), postprandial glucose (from 216.9 6 37.2 mg/dL to 191.1 6 40.9 mg/dL; P = 0.008), total cholesterol (from 223 6 32 mg/dL to 184 6 29 mg/dL; P , 0.001), and triglyceride levels (from 203 6 123 mg/dL to 175 6 92 mg/dL). 65 A similar study was carried out to investigate the glycemic and lipid effects of colestimide in 70 patients with type 2 diabetes receiving treatment with oral antidiabetic agents or insulin who had baseline LDL-C .3.6 mmol/L. 66 Following 12 weeks of treatment with 3 g/d colestimide, significant reductions in A1C (from 7.7 6 0.7% to 6.8 6 0.5%; P , 0.01), total cholesterol (from 5.5 6 0.9 mmol/L to 4.8 6 0.6 mmol/L; P , 0.01), and LDL-C (from 3.5 6 0.8 mmol/L to 2.7 6 0.5 mmol/L; P , 0.01) were reported, suggesting that colestimide may be clinically useful, providing dual effects on glycemic control and the lipid profile in patients with type 2 diabetes.…”

Section: Clinical Evidence Of Bile Acid Sequestrants Improving Glycemmentioning

confidence: 99%

Reducing Cardiovascular Complications of Type 2 Diabetes by Targeting Multiple Risk Factors

Reasner¹

2008

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Insulin resistance syndrome is characterized by hyperglycemia, atherogenic dyslipidemia, hypertension, and abdominal obesity. Hyperglycemia is the major risk factor for microvascular complications in type 2 diabetes. However, 70% to 80% of patients with type 2 diabetes will die of macrovascular disease. Atherogenic dyslipidemia-characterized by elevated triglyceride levels, low high-density lipoprotein cholesterol (HDL-c) levels, and a preponderance of small, dense, low-density lipoprotein (LDL) particles-is the major cause of atherosclerosis in individuals with type 2 diabetes. Therefore, treatment of type 2 diabetes must address hyperglycemia to prevent microvascular disease (retinopathy, neuropathy, and nephropathy) and atherogenic dyslipidemia to prevent macrovascular complications. Emerging evidence indicates lipid and glucose homeostasis are interrelated via bile acid-activated nuclear hormone receptor signaling pathways. Agents that act on these pathways could simultaneously address hyperglycemia and dyslipidemia in patients with type 2 diabetes. Recent studies have shown that bile acid sequestrants, including cholestyramine, colestimide, and colesevelam HCl, significantly improve glycemic control and reduce LDL cholesterol levels in patients with type 2 diabetes. This paper will review the effects of bile acid sequestrants on both glucose and lipid metabolism in patients with type 2 diabetes.

show abstract

“…Because BAR is not absorbed systemically, it is not thought to have systemic effects. However, recent clinical reports have revealed that BAR improves dyslipidaemia and glycaemic control in patients with type 2 diabetes mellitus [2][3][4][5][6][7][8]. Several different types of BAR are used worldwide, including colesevelam, colestipol, and colestilan.…”

Section: Introductionmentioning

confidence: 99%